VRTX · 10-Q · 2026Q3 · Full report
Acquisition / Partnership / Divestiture
VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 71 · Surprise 60 · In source text
Vertex completed its acquisition of Crinetics in September 2026 for $85.00 per share in cash, representing $10.0 billion of equity value and $9.0 billion net of acquired cash, cash equivalents and marketable securities.,Vertex financed the acquisition using cash and marketable securities plus $4.5 billion borrowed under the 2026 Term Loan.,The business combination added $8.1 billion of intangible assets to the balance sheet and brought PALSONIFY into Vertex's commercial portfolio.,Vertex recorded $62.5 million of AIPR&D in the first nine months of 2026, including upfront, contingent milestone or other payments under business development transactions.
Key facts
- Vertex completed the Crinetics acquisition in September 2026 for $85.00 per share in cash, representing $10.0 billion total equity value or $9.0 billion net of cash acquired. source
- The Crinetics acquisition was accounted for as a business combination and resulted in $8.1 billion of additional intangible assets being recorded. source
- Vertex acquired Alpine Immune Sciences and povetacicept in 2024 for approximately $5.0 billion; $4.4 billion of the fair value attributed to povetacicept was expensed as AIPR&D in 2024. source
- Vertex used $6.6 billion of investing cash in the first nine months of 2026, primarily for $9.1 billion paid to acquire Crinetics net of acquired cash, partly offset by $2.8 billion of net sales and maturities of available-for-sale debt securities. source
- Vertex out-licensed povetacicept to Zai Lab in January 2025 for mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore; Vertex is eligible for future milestone payments and tiered royalties on sales in those territories. source
- Vertex out-licensed povetacicept to Ono in June 2025 for Japan and South Korea; Vertex is eligible for future milestone payments and tiered royalties on sales in the licensed regions. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +24.7% | The Crinetics acquisition was accounted for as a business combination and resulted in $8.1 billion of additional intangible assets being… |
| revenue | positive | contingent | — | Vertex out-licensed povetacicept to Zai Lab in January 2025 for mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore;… |
| revenue | positive | contingent | — | Vertex out-licensed povetacicept to Ono in June 2025 for Japan and South Korea; Vertex is eligible for future milestone payments and… |